Back to Search
Start Over
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
- Source :
- The Journal of Allergy and Clinical Immunology, Journal of Allergy and Clinical Immunology
- Publication Year :
- 2020
- Publisher :
- American Academy of Allergy, Asthma & Immunology, 2020.
-
Abstract
- The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being "immune" to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration-approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.
- Subjects :
- 0301 basic medicine
SARS, Severe acute respiratory syndrome
ACE2
Disease
medicine.disease_cause
0302 clinical medicine
NIH, National Institutes of Health
Pandemic
Immunology and Allergy
CoV, Coronavirus
030212 general & internal medicine
CDC, Centers for Disease Control and Prevention
Coronavirus
COVID-19, Coronavirus disease 2019
Transmission (medicine)
MERS-CoV, Middle East respiratory syndrome coronavirus
TMPRSS2, Transmembrane protease serine S1 member 2
RSV, Respiratory syncytial virus
receptor-binding domain
JAK, Janus kinase
Viral load
severe acute respiratory syndrome coronavirus 2
Middle East respiratory syndrome coronavirus
Immunology
Article
SARS-CoV, Severe acute respiratory syndrome coronavirus
WHO, World Health Organization
03 medical and health sciences
Viral entry
ACE2, Angiotensin-converting enzyme 2
ARDS, Acute respiratory distress syndrome
medicine
RV, Rhinovirus
TMPRSS2
MX1, MX dynamin-like GTPase 1
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
allergic rhinitis
business.industry
MERS, Middle East respiratory syndrome
COVID-19
S protein, Spike glycoprotein
asthma
medicine.disease
FDA, Food and Drug Administration
030104 developmental biology
IDO, Indoleamine 2,3-dioxygenase
RBD, Receptor-binding domain
Middle East respiratory syndrome
business
MMWR, Morbidity and Mortality Weekly Report
Subjects
Details
- Language :
- English
- ISSN :
- 10976825 and 00916749
- Database :
- OpenAIRE
- Journal :
- The Journal of Allergy and Clinical Immunology
- Accession number :
- edsair.doi.dedup.....31e3908a6acf7e231e7354933c932f73